NCT05965284View on ClinicalTrials.gov

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
ANCA-associated VasculitisMaintenance Therapy
Interventions
DRUG

Azathioprine

All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.

DRUG

Telitacicept

Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Chinese SLE Treatment And Research Group

OTHER